Cited by 135Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and Analysis

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

Open access

Das, Satya, Al-Toubah, Taymeyah, El-Haddad, Ghassan, Strosberg, Jonathan·2019·Expert Review of Gastroenterology & Hepatology

DOI 10.1080/17474124.2019.1685381PMC PMC7227421

Open this paper in CoChat — free account

Abstract

Introduction: 177Lutetium-[DOTA°,Tyr3]octreotate (177Lu-DOTATATE) is a type of peptide receptor radionuclide therapy that garnered FDA approval in January 2018 for the treatment of somatostatin receptor-positive gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients. The therapy approval was based on findings from the randomized international phase III NETTER-1 trial as well as outcome data from a large European registry. The mechanism of the drug stems directly from its structure: a somatostatin analog (octreotate) selectively binding to somatostatin receptor expressing cells and being internalized, along with a chelated beta-emitting isotope 177Lu.Areas Covered: Herein we describe the pharmacology, clinical efficacy and adverse event data from prospective and retrospective studies with 177Lu-DOTATATE. We discuss the role of 177Lu-DOTATATE within the current treatment landscape for GEP NET patients.Expert Opinion: 177Lu-DOTATATE represents a unique addition to the treatment armamentarium for GEP NETs because of its potential to elicit tumor cytoreduction, which is rare among other existing treatment options, and prolonged disease control. Where 177Lu-DOTATATE fits into the treatment sequence for GEP NET patients remains an area of active investigation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/17474124.2019.1685381

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Dasari, A. N., Shen, C., Halperin, D. M., Zhao, B., Zhou, S., Xu, Y., Shih, Y. T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,457 · cited 2×
“Article highlights ● 177Lu-DOTATATE is a radiolabeled somatostatin agonist (SSA), which is approved for the treatment of somatostatin receptor positive welldifferentiated gastroenteropancreatic (GEP) neuroendocrine tumor (NET) patients in Europe, the United States, and Canada.”
Background
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · cited 1×
“The NETTER-1 study was a randomized phase III trial in patients with progressive metastatic or unresectable well-differentiated midgut neuroendocrine tumors [34].”
BackgroundSelf-citation
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, É., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard‐Bohas, C., Valle, J. W., Metrakos, P. P., Smith, D. M., Vinik, A. I., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · cited 1×
“proven cytostatic activity for pancreatic NETs only [8].”
Background
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Rinke, A., Müller, H., Schade‐Brittinger, C., Klose, K., Barth, P. J., Wied, M., Mayer, C., Aminossadati, B., Pape, U., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,507 · cited 1×
“or those with hormonal over-production leading to syndromes, long-acting somatostatin agonists (SSAs) have been the cornerstone of first-line therapy [4,5].”
Background
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M. E., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,937 · cited 1×
“or those with hormonal over-production leading to syndromes, long-acting somatostatin agonists (SSAs) have been the cornerstone of first-line therapy [4,5].”
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E. M., Tomášek, J., Raderer, M., Lahner, H., Voi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,290
Self-citation
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas
Oronsky, B. T., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.002 · Cited by 766 · cited 1×
“Gastroenteropancreatic (GEP) NETs represent the most common subtype of well-differentiated NETs, comprising more than 70% of these neoplasms [2].”
Background
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
Strosberg, J., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J. F., & Kvols, L. K. (2010) · Cancer · doi:10.1002/cncr.25425 · Cited by 763
Self-citation
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [ 90 Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H. F., Mäcke, H. R., Rochlitz, C. F., Müller‐Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 641 · cited 1×
“2% experienced permanent nephrotoxicity (grade ≥ 4) [29].”
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2743 · Cited by 616 · cited 1×
“NETs) received treatment with (177)Lu-DOTATATE [37].”
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P. M., Konijnenberg, M., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. E., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100574 · Cited by 470
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Bodei, L., Cremonesi, M., Grana, C. M., Fazio, N., Iodice, S., Baio, S. M., Bartolomei, M., Lombardo, D., Ferrari, M. E., Sansovini, M., et al. (2011) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-1902-1 · Cited by 433
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 432
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
Kwekkeboom, D. J., Bakker, W. H., Kam, B. L. R., Teunissen, J. J. M., Kooij, P. P. M., de Herder, W. W., Feelders, R. A., van Eijck, C. H. J., de Jong, M., Srinivasan, A., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1050-8 · Cited by 426
Yttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R. P., Heppeler, A., Béhé, M. P., Jermann, E., Powell, P., Maëcke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 421
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study
Waldherr, C., Pless, M., Maëcke, H. R., Haldemann, A. R., & Mueller‐Brand, J. (2001) · Annals of Oncology · doi:10.1023/a:1011160913619 · Cited by 396
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177 Lu-Dotatate in the Phase III NETTER-1 Trial
Strosberg, J., Wolin, E. M., Chasen, B., Kulke, M. H., Bushnell, D. L., Caplin, M. E., Baum, R. P., Kunz, P. L., Hobday, T. J., Hendifar, A. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5865 · Cited by 391 · cited 1×
“A quality of life (QOL) analysis of the NETTER-1 trial was published separately [36].”
BackgroundSelf-citation
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
Rolleman, E., Valkema, R., de Jong, M., Kooij, P., & Krenning, E. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0982-3 · Cited by 321 · cited 3×
“positively charged amino acids such as L-arginine and L-lysine is used to decrease renal radiation exposure [25,26].”
BackgroundMethod
Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship.
Barone, R., Borson‐Chazot, F., Valkema, R., Walrand, S., Chauvin, F., Gogou, L., Kvols, L. K., Krenning, E. P., Jamar, F., & Pauwels, S. A. (2005) · PubMed · Cited by 289
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
Anthony, L. B., Woltering, E. A., Espenan, G. D., Cronin, M. D., Maloney, T. J., & McCarthy, K. E. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc.2002.31769 · Cited by 277 · cited 2×
“to the small range and limited tissue penetration [12].”
Background
Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study
Wild, D., Fani, M., Fischer, R., Pozzo, L. D., Kaul, F., Krebs, S. S., Fischer, R., Rivier, J., Reubi, J. C., Maëcke, H. R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138834 · Cited by 267
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience
Fine, R. L., Gulati, A. P., Krantz, B. A., Moss, R. A., Schreibman, S. M., Tsushima, D. A., Mowatt, K. B., Dinnen, R. D., Mao, Y., Stevens, P. D., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2055-z · Cited by 252
Lutetium-labelled peptides for therapy of neuroendocrine tumours
Kam, B. L. R., Teunissen, J. J. M., Krenning, E. P., de Herder, W. W., Khan, S., van Vliet, E. I., & Kwekkeboom, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2039-y · Cited by 247 · cited 1×
“Octreotate [D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr] is a slightly modified form of the commercially available SSA octreotide in which the C-terminal threoninol is replaced with threonine, resulting in an enhanced affinity to somatostatin receptor subtype 2 [22].”
Background
86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion
Jamar, F., Barone, R., Mathieu, I., Walrand, S., Labar, D., Carlier, P., Camps, J., SCHRAN, H. F., Chen, T., Smith, M. C., et al. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1117-1 · Cited by 240 · cited 3×
“positively charged amino acids such as L-arginine and L-lysine is used to decrease renal radiation exposure [25,26].”
Background
Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?
Esser, J.-P., Krenning, E. P., Teunissen, J. J. M., Kooij, P. P. M., van Gameren, A. L. H., Bakker, W. H., & Kwekkeboom, D. J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0172-9 · Cited by 179
Somatostatin and Other Peptide Receptors as Tools for Tumor Diagnosis and Treatment
Reubi, J. C. (2004) · Neuroendocrinology · doi:10.1159/000080742 · Cited by 152 · cited 1×
“Somatostatin receptors are expressed in >80% of well-differentiated NETs, with somatostatin receptor subtype 2 being the most prevalent subtype [3].”
Background
Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.
Forrer, F., Uusijärvi, H., Storch, D., Maëcke, H. R., & Mueller‐Brand, J. (2005) · PubMed · Cited by 146
Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms
Baum, R. P., Kulkarni, H. R., Singh, A., Kaemmerer, D., Mueller, D., Prasad, V., Hommann, M., Robiller, F. C., Niepsch, K., Franz, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24524 · Cited by 141 · cited 1×
“patients who underwent PRRT with either (177)Lu-DOTATATE, (90)Y-DOTATOC or both therapies in an alternating fashion [38].”
Background
Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models
Dalm, S. U., Nonnekens, J., Doeswijk, G. N., de Blois, E., van Gent, D. C., Konijnenberg, M., & de Jong, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167007 · Cited by 137 · cited 2×
“In vitro experiments comparing 177Lu-OPS201 to 177Lu-DOTATATE in osteosarcoma cells transfected with somatostatin receptor 2, demonstrated that the former compound accumulates at cell membrane surfaces rather than being internalized and elicits more doublestranded DNA breaks (as measured by 53BP1 and DAP1) [48].”
Background
Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors
Delpassand, E. S., Samarghandi, A., Zamanian, S., Wolin, E. M., Hamiditabar, M., Espenan, G. D., Erion, J. L., O’Dorisio, T. M., Kvols, L. K., Simón, J., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000113 · Cited by 136
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
Bodei, L., Kidd, M. S., Singh, A., van der Zwan, W. A., Severi, S., Drozdov, I. A., Ćwikła, J. B., Baum, R. P., Kwekkeboom, D. J., Paganelli, G., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3967-6 · Cited by 134 · cited 1×
“A PRRT predictive quotient (PPQ) stratifying responders from non-responders was validated in 178 NET patients treated with (177)Lu-DOTATATE across three cohorts [40].”
Method
Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
van Essen, M., Krenning, E. P., Kam, B. L. R., de Herder, W. W., Feelders, R. A., & Kwekkeboom, D. J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.068957 · Cited by 123
Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients
Zhang, J., Kulkarni, H., Singh, A., Niepsch, K., Müller, D., & Baum, R. P. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215848 · Cited by 122
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.
Reidy-Lagunes, D., Pandit-Taskar, N., O'Donoghue, J. A., Krebs, S., Staton, K. D., Lyashchenko, S. K., Lewis, J. S., Raj, N., Gönen, M., Lohrmann, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1026 · Cited by 112 · cited 1×
“a phase I study of (177)Lu-OPS201 in 20 (45% PNET) refractory well-differentiated NET patients [50].”
Background
Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog 177 Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
Zhang, J., Wang, H., Jacobson, O., Cheng, Y., Niu, G., Li, F., Bai, C., Zhu, Z., & Chen, X. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.209841 · Cited by 104 · cited 1×
“A phase I Chinese study of (177)Lu-DOTA-EB-TATE explored safety and dosimetry of a single dose of the drug [47].”
Background
Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors
Haug, A. R., Rominger, A., Mustafa, M., Auernhammer, C. J., Göke, B., Schmidt, G. P., Wängler, B., Cumming, P. D., Bartenstein, P., & Hacker, M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089276 · Cited by 78
Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
Cherk, M. H., Kong, G., Hicks, R. J., & Hofman, M. S. (2018) · Cancer Imaging · doi:10.1186/s40644-018-0136-x · Cited by 73
Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms
Al‐Toubah, T., Morse, B. G., & Strosberg, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0361 · Cited by 73
Self-citation
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC
Severi, S., Sansovini, M., Ianniello, A., Bodei, L., Nicolini, S., Ibrahim, T., Iorio, V. D., D’Errico, V., Caroli, P., Monti, M., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3105-7 · Cited by 72
Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms
Chatzellis, E., Angelousi, A. G., Daskalakis, K., Tsoli, M., Alexandraki, K., Wachuła, E., Meirovitz, A., Maimon, O., Grozinsky‐Glasberg, S., Gross, D., et al. (2019) · Neuroendocrinology · doi:10.1159/000500135 · Cited by 70
Long-Acting Somatostatin Analog Therapy Differentially Alters68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions
Ayati, N., Lee, S. T., Zakavi, S. R., Pathmaraj, K., Al-Qatawna, L., Poon, A. M. T., & Scott, A. M. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.192203 · Cited by 61
Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo
White, B. H., Whalen, K. A., Kriksciukaite, K., Alargova, R. G., Yeung, T. P. A., Bazinet, P., Brockman, A. H., DuPont, M. M., Oller, H. R., Lemelin, C.-A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b02036 · Cited by 57 · cited 1×
“PEN-221 is a SSA conjugated to the chemotherapeutic agent mertansine (DM1), which is a microtubule inhibitor [51].”
Background
Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma — retrospective analysis
Rogowski, W., Wachuła, E., Gorzelak-Magiera, A., Lebiedzińska, A., Sulżyc-Bielicka, V., Iżycka‐Świeszewska, E., Żołnierek, J., & Kos‐Kudła, B. (2019) · Endokrynologia Polska · doi:10.5603/ep.a2019.0010 · Cited by 46
CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience
Sahu, A., Jefford, M., Lai-Kwon, J. E., Thai, A. A., Hicks, R. J., & Michael, M. (2019) · Journal of Oncology · doi:10.1155/2019/9032753 · Cited by 44
Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response
Owen, D. H., Alexander, A. J., Konda, B., Wei, L., Hemminger, J. A., Schmidt, C. R., Abdel‐Misih, S., Dillhoff, M. E., Sipos, J. A., Kirschner, L. S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22001 · Cited by 42
Essentials of Nuclear Medicine and Molecular Imaging
(2019) · Elsevier eBooks · doi:10.1016/c2016-0-00043-8 · Cited by 36
Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours
Papaxoinis, G., Kordatou, Z., McCallum, L., Nasralla, M., Lamarca, Á., Backen, A. C., Nonaka, D., & Mansoor, W. (2019) · Neuroendocrinology · doi:10.1159/000502864 · Cited by 34
First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.
Strosberg, J., Wolin, E. M., Chasen, B. A., Kulke, M. H., Bushnell, D. L., Caplin, M. E., Baum, R. P., Hobday, T. J., Hendifar, A. E., Sierra, M. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4099 · Cited by 28 · cited 1×
“4 months while still had not been reached in the (177)Lu-DOTATATE arm [35].”
BackgroundSelf-citation
First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.
Johnson, M. L., Meyer, T., Halperin, D. M., Fojo, A. T., Cook, N., Blaszkowsky, L. S., Schlechter, B. L., Yao, J. C., Jemiai, Y., Kriksciukaite, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.4097 · Cited by 26 · cited 1×
“Findings from the doseescalation portion of the phase I/II study of PEN-221 in NET and small cell lung carcinoma (SCLC) patients were presented at ASCO 2018 [52].”
Method
PRRT: Defining the Paradigm Shift to Achieve Standardization and Individualization
Bodei, L., Kidd, M. S., Baum, R. P., & Modlin, I. M. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.143974 · Cited by 22
Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Progressive Grade 3 Neuroendocrine Neoplasms (NEN)
Zhang, J., Kulkarni, H., Singh, A., Niepsch, K., Müeller, D., & Baum, R. P. (2019) · Journal of Nuclear Medicine · Cited by 2
The failure of clinical factors to predict long-term toxicity after PRRT in >800 patients - Is a genetic screen needed?
Bodei, L., Kidd, M. S., Paganelli, G., Grana, C. M., Drozdov, I. A., Cremonesi, M., & Modlin, I. M. (2014) · Journal of Nuclear Medicine · Cited by 1

Research works printed but not linked: 4

Barone R, 2005, J Nucl Med, 46, 99S
Strosberg J, 2018, J Clin Oncol, 36(25):2578–258
Zhang J, 2019, J Nucl Med, 60, 560
Forrer F, 2005, J Nucl Med, 46, 1310

Sorted by citations

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00572-6 · Cited by 605
Self-citation
Targeted α -Emitter Therapy with 212 Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
Delpassand, E. S., Tworowska, I., Esfandiari, R., Torgue, J., Hurt, J., Shafie, A., & Núñez, R. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263230 · Cited by 199
“Food and Drug Administration for patients with SSTR-expressing gastroenteropancreatic NETs (5).”
Background
Targeted alpha therapy: progress in radionuclide production, radiochemistry, and applications.
Nelson, B. J. B., Andersson, J. D., & Wuest, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010049 · Cited by 194
“Clinical success has been demonstrated with the β− emitters 90Y and 131I conjugated with anti-CD20 monoclonal antibodies in follicular B-cell non-Hodgkin lymphoma [6], 177Lu-labeled prostate-specific membrane antigen (PSMA) peptides in metastatic, castrationresistant prostate cancer (CRPC) and 177Lu-DOTATATE for neuro…”
Background
Peptide–drug conjugate-based novel molecular drug delivery system in cancer
Zhu, Y., Tang, K., & Lv, J. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.07.001 · Cited by 157
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Dhoundiyal, S., Srivastava, S., Kumar, S., Singh, G., Ashique, S., Pal, R., Mishra, N., & Taghizadeh-Hesary, F. (2024) · European Journal of Medical Research · doi:10.1186/s40001-023-01627-0 · Cited by 144
“An excellent example is 177 Lu-DOTATATE, a radiolabelled somatostatin analogue, used to treat neuroendocrine tumors (NETs) [91].”
Background

See all 135

Authors: Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J.
Affiliations: Vanderbilt University Medical Center (US)
Department of GI Oncology, Moffitt Cancer Center, Tampa, FL, USA
Moffitt Cancer Center (US)
Corresponding author: Das, Satya
ORCID: Das, Satya
El-Haddad, Ghassan
Strosberg, Jonathan
Venue: Expert Review of Gastroenterology & Hepatology
Publisher: Informa UK Limited
Published: 2019-10-30
Volume: 13
Issue: 11
Pages: 1023-1031
ISSN: 1747-4124 (ISSN-L)
1747-4132
DOI: 10.1080/17474124.2019.1685381
PMC: PMC7227421
OpenAlex: W2981499856
Cited by: 135
References: 53
Citations by year: 2026: 23 · 2025: 32 · 2024: 32 · 2023: 15 · 2022: 20 · 2021: 9 · 2020: 4
FWCI: 6.28
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Expert Review of Gastroenterology & Hepatology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K12CA090625)
Topics: Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
Keywords: 177Lu-DOTATATE, peptide receptor radionuclide therapy, gastroenteropancreatic neuroendocrine tumors, somatostatin receptors, octreotate, NETTER-1 trial, treatment efficacy, adverse events, treatment sequencing
MeSH terms: Animals, Gastrointestinal Neoplasms, Humans, Organometallic Compounds, Pancreatic Neoplasms, Octreotide, Treatment Outcome, Neuroendocrine Tumors, Radiopharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks